Member Info for dallo

Golfnut

Management and directors no longer in control here.

The big Institutional shareholders are calling the shots

now and Lyne is there to do a job in their ( and our) interests.

Staff being laid off and a " For Sale" sign on the door .

That is now the strategy imho.

I fully expect a bid soon which is why I added today..

The fact they haven't appointed a full-time Chairman and CEO tells it's own tale.

End game in sight imho

Investhome

The hub and spoke strategy of the past 6 years was supposed to deliver a $10b company according to Zohar.

It has delivered just 1 success albeit a big one in Karuna sold for $14b.

The SP is at an all time low and inflation adjusted even worse.

If the strategy had worked we would be rich today.

The reality is different and accordingly we need a new approach imho.

Golfnut

Precisely the reason I hope a bid stops this happening as the hub and spoke model is hated by investors and Puretech lost out on Cobenfy to the tune of $13b by not acting as a proper public Pharma development company.

Doing the same with Celea when we have c$300m in cash is mind boggling.

I hope Lyn is not another collect the paycheck and don't rock the boat merchant.

United Therapeutics market cap up in pre market trading by c $5b on IPF Phase 3 results.

Demonstrates the prize for Puretech with LYT-100 if Phase 3 is successful.

Golfnut

Spot on...that's the reason indeed

However LYT-100 still a powerful treatment too but needs to push on to Phase 3 .

Twr

Highly unlikely that shorts closed because of impending bid or a leak of such news.

Puretech has already rejected a bid from Nortic Capital and the market reacted with a yawn .

I still feel we will get some concrete news soon and as such I have added another 25,000 shares with my breakeven now at £1.40 ish.

I am looking at numerous pharma deals for even early stage drug assets at incredibly high prices and M&A activity has certainly picked in the Global pharma sector of late.

With an Interim Chairman and CEO in situ and staff levels in Puretech being dramatically reduced , it has all the hallmarks of a company ripe for takeover imho.

The collapse in the share price today looks very suspicious in my view and the pressure in firmly on the Directors to respond .

Hopefully Robert Lyn can meet the challenge.

ATB

Golfnut

I don't blame you for being utterly perplexed .

I have been an investor in the markets for over 50 years and have never encountered a share like Puretech where even good news is punished and where there is relentless selling over a long period for no apparent reason.

We are now close to all time lows again and absolutely no support for the share.

Maybe time to buy again !!!

JSB

Agree with your comments.

The other possibility is a bid from BMS .

Even if BMS were to offer say $800m , it would get cash of c$300m plus potential savings on Cobenfy royalties of c$300m ( non discounted) and get all of Celea , Gallop and shareholding in Seaport for just c$200m.

Seems like a no brainer to me but nonetheless selling continues unabated .

Patience as always but I will hang on for a while.

Golfnut

Very good analysis of the current position of Puretech.

Here's the thing...if outside investor (s) are willing to fund Celea to the tune of say $300m for a 50/60% shareholding then surely the logical course of action is for PE investor to offer say $600m for Puretech and get cash of $320m , Royalties from Cobenfy of say $300m and ALL of Celea and Gallop plus share in Seaport.

With confidence in Puretech's management and shareholders' satisfaction at an all time low, now is the time for an opportunistic bid .

£2 or a little higher would seal the deal imho.

JSB

Thanks for that.

Cheers

JSB

Thanks for that.

I have missed the presentation as I was stuck at a meeting.

Any mention of the share price underperformance and possible buybacks?

Market reaction today is scathing .

Hopefully better days ahead

Cheers

JSB

On the face of it nothing to inspire investors in the Half Year Report with much of the same old platitudes and catalysts further down the road.

However a few specks of gold dust in the sand in the promise to examine return mechanisms once Celea and Gallop are funded which I read as another buy back programme .

Also the appointment of two experienced Non Executive Directors to cultivate the UK listing and engage with UK Institutions is long overdue.

I think Puretech is now extremely vulnerable to a bid and a share buyback may not come in time to save it.

Rob sounds like a guy who is here for a short stay with a specific mission hopefully to accommodate a sale.

The market reaction says it all...investors just not interested in Puretech's strategy , management and continuing promises of riches somewhere over the rainbow.

Down 5%

Unreal

Malt

I agree with you on the pain we are suffering as shareholders here after 6 years as an investor myself.

A small bounce last week and today down 5p , a trend that has continued for years .

Most investors both Institutional and private would accept a reasonable exit and move on.

I will hang in for another few months and see what happens.

I have written to the company about the share price underperformance and inept management particularly after the previously undisclosed Convertible Loan debacle in Vedanta was revealed in a footnote in the RNS a week or so ago.

I have stressed to management the urgent need to maximise shareholder value and the importance of the upcoming Interims in outlining the new management's plans .

We shall see more in Thursday.

Jamgoo

It all depends on the financing structure of Celea and how much is raised from external investors, how much Puretech contribute to the overall financing and most importantly what % shareholding retain in the funded Celea as it progresses LYT-100 through the Phase 43 trial.

Any shareholding held by Puretech below 50% would be a major disappointment given the late stage nature of LYT-100.

We are entering a critical period now with the Interims next week and the FDA agreement on the Phase 3 protocols imminent.

Fingers crossed and it appears interest in LYT-100 has been heightened by the latest findings on LYT-100 announced at the conference in Boston last week.

JSB

Puretech also has Gallop Oncology and its research and development facilities and people are hugely respected In the US Pharma sector.

Hopefully some interesting news at the Interims RNS.

Well I was nearly right insofar as there was a large Convertible Debt to Equity swap done in Vedanta in recent months as part of the 2023 Financing .

In effect the Convertible Debt holders took control of Vedanta and diluted the equity holders by nearly 85%.

Puretech has confirmed this and said its valuation of its shareholding in Vedanta was always low given the Convertible Debt looming over equity holders.

I suggested they clarify this fact to the market to avoid investor concerns over our other major founded companies, Seaport and Celea.

So good old AI was right about the recent share issue in the Debt/Equity swap and being part of the overall 2023 financing package.

The interims are going to be interesting and it appears that the company is acutely aware of their importance.

ATB

803

Yes this is even more baffling than a financing round dilution.

I have asked the company to clarify.

Cheers

Oldernowiser

Apologies to you for getting my funding dates wrong.

Your comments regarding what happened to Puretech's shareholding in Vedanta are valid.

I feel a bit of an idiot but what's new..doh!!!

Major correction

The Vedanta fund raise of c$106 m took place in April 2023 not 2025 and Puretech did participate then and was not diluted .

I am sorry for misleading you all on this but it raises an even more disquieting issue....how was Puretech suddenly diluted if there was no fund raise this year in Vedanta.

Apologies again ...the perils of AI